Lab capabilities are advancing fast, but progress could be undermined by legacy QC technology infrastructure.

Biopharma organizations have to balance competing forces as they approach commercialization. From the early stages of drug development, their teams must be ready to scale their activities efficiently without adding cost or slowing time to market. However, scientific advances in new modalities mean products are more complex and costly to manufacture and test. Given the increasing regulatory scrutiny of virtual biotech, even sponsor companies outsourcing these activities must efficiently scale their external partner and quality control (QC) oversight.

In this article, you’ll learn about common misconceptions hindering change — and why moving past them early is a competitive advantage when preparing to commercialize.